UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Copik, Alicja J.
Hasan, Md Faqrul
Croom-Perez, Tayler
Abrégé
Disclosed herein are engineered NK cells that are suppressed in the expression of T Cell Immunoreceptor with Ig And ITIM Domains (TIG IT), TIGIT expression suppressed by a deletion of a TIGIT gene or a fragment thereof utilizing a CRISPR/Cas endonuclease (Cas)9 system, and uses thereof for treating cancers and infectious diseases.
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Khaled, Annette
Zhai, Lei
Mckinstry, Kai
Nierenberg, Daniel
Abrégé
Disclosed are nanoparticle compositions and methods for treating cancer. Further, hyperbranched polyester (HBPE) nanoparticle that comprise one or more coronal proteins are disclosed herein.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/553 - Support métallique ou recouvert d'un métal
4.
METHOD AND APPARATUS FOR ENHANCING OPERATION OF LEG PROSTHESIS
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Choi, Hwan
Ramezani, Sepehr
Abrégé
A method and an apparatus for enhancing operation of a leg prothesis is provided. The apparatus includes a variable stiffness module configured to be attached between a first portion and a second portion of a leg prothesis. The first portion is configured to move relative to the second portion in a first plane. The variable stiffness module defines an interior region configured to store pressurized fluid. A volume of the interior region is configured to be varied from a first volume to a second volume such that a stiffness of the variable stiffness module in the first plane is varied from a first stiffness to a second stiffness.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Choi, Hwan
Abrégé
A method and apparatus for enhancing the operation of leg prothesis is provided. The apparatus includes a core configured to be attached between a first portion and a second portion of the leg prothesis. The first portion is configured to move relative to the second portion in a first plane. The core is configured to be moved from a first position to a second position relative to the leg prothesis such that a stiffness of the core in the first plane is varied from a first stiffness to a second stiffness. The method includes the step of attaching the core between the first portion and the second portion of the leg prothesis. The method further includes moving the first portion relative to the second portion in a first plane. The method further includes moving the core with a motor from a first position to a second position relative to the leg prothesis such that a stiffness of the core in the first plane varies from a first stiffness to a second stiffness.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Copik, Alicja
Oyer, Jeremiah
Dieffenthaller, Thomas
Parks, Griff
Abrégé
Compositions and methods for stimulating ?? T cell expansion and cytotoxicity are described. Therapeutic compositions and methods using expanded and stimulated ?? T cells are described.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Strutt, Tara M.
Mckinstry, Karl Kai
Abrégé
Disclosed are compositions comprising an IL-2:anti-IL-2 antibody (Ab) complex (IL-2C) and methods of using said compositions for the treatment of microbial infections, autoimmune diseases, autoinflammatory diseases, or cancers as well the treatment of inflammatory conditions or reduction in inflammation caused by said microbial infections, autoimmune diseases, autoinflammatory diseases, or cancers.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
KISMET TECHNOLOGIES INC. (USA)
Inventeur(s)
Seal, Sudipta
Neal, Craig
Drake, Christina Hartsell
Abrégé
Disclosed herein are rapid and residual disinfectant compositions that include a metal-associated cerium oxide nanoparticles. Also disclosed are methods of making disinfectant compositions. Films comprising the disclosed compositions are also disclosed as well as methods of disinfecting a surface.
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
A61L 2/16 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des substances chimiques
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Sugaya, Kiminobu
Smith, Jonhoi
Abrégé
Methods and agents that target nanog or Oct4 expression or activity for treating or preventing cancer are disclosed. Alternative methods involve diagnosing cancer stage or type by identifying presence of cancer cells expressing nanog or Oct4. Also, disclosed are method of treating coronavirus infection that involves administering antiviral knockdown agents, such as oligonucleotide-based inhibitors.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
AXOSIM, INC. (USA)
Inventeur(s)
Rajaraman, Swaminathan
Didier, Charles M.
Kundu, Avra
Curley, Lowry
Moore, Michael J.
Nguyen, Hieu
Rountree, Corey
Abrégé
Disclosed herein are novel 3D microelectrode arrays (3D MEA) that include a substrate body (e.g. chip), microneedles, traces, and a well, wherein the 3D MEA provides for transfer of electrical signals on one side of the substrate body to the other side of the substrate body. Methods for using 3D MEAs to grow electrogenic cells and obtain electrophysiological signals are disclosed as well. Fabrication techniques for producing the 3D MEAs are also disclosed.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Choi, Hwan
Carbonell, Gabriel Rios
Abrégé
A method and apparatus for enhancing the operation of leg prothesis is provided. The apparatus includes a cable configured to be attached to the leg prosthesis worn by a subject to move through a plurality of gait phases. The apparatus also includes a module configured to be mounted to the leg prosthesis. The module includes a tension spring configured to engage the cable to maintain tension in the cable. The module also includes a locking mechanism configured to lock a position of the tension spring and maintain a length of the cable defined between the module and the leg prosthesis during at least one first gait phase of the plurality of gait phases. The locking mechanism is further configured to unlock the position of the tension spring to permit variation of the length of the cable during at least one second gait phase of the plurality of gait phases.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Copik, Alicja
Parks, Griffith
Oyer, Jeremiah
Abrégé
Described herein is a natural killer (NK) cell expanding composition comprising a membrane-bound inverted Fc domain bound to an external surface of a feeder cell, an engineered plasma membrane (PM) particle, or an exosome, wherein the inverted Fc domain is part of a fusion protein comprising a transmembrane domain linked to the amino terminus of an Fc domain, the amino terminus of the Fc domain facing the external surface of the feeder cell, engineered PM particle, or engineered exosome. An NK cell composition comprising an in vitro NK cell population in contact with an NK cell expanding composition is also described. Various therapeutic uses of said NK cell populations and compositions are also disclosed. The described compositions and NK cell populations are useful in the treatment of various diseases, including various cancers.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (USA)
Inventeur(s)
Phanstiel, Otto
Massaro, Chelsea
Thomas, Jenna
Nefzi, Adel
Abrégé
Novel compounds are described which decrease the intracellular levels of leucine and methionine. Treatment with these amino acid depletion agents affects many metabolic and life processes which rely upon methionine, leucine and their derivatives. Methionine depletion not only inhibits protein synthesis, but also polyamine biosynthesis and significantly reduces intracellular pools of the native polyamines, spermidine and spermine. Since methionine restriction has been shown to mimic caloric restriction in life extension studies across multiple species, these compounds are also expected to extend lifespan by limiting methionine supply.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
14.
ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (USA)
Inventeur(s)
Phanstiel Iv, Otto
Moots, Holly
Maloney, Patrick
Hershberger, Paul
Peddibhotla, Satyamaheshwar
Abrégé
Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.
C07D 295/155 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de car avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile avec les atomes d'azote du cycle et les atomes de carbone comportant trois liaisons à des hétéro-atomes séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4402 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 2, p.ex. phéniramine, bisacodyl
A61K 31/443 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07D 207/06 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
C07D 239/28 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant au moins trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone du cycle
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
15.
DETECTION OF INTERACTION BETWEEN AN ASSAY SUBSTANCE AND BLOOD OR BLOOD COMPONENTS FOR IMMUNE STATUS EVALUATION DISEASE DETECTION
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Huo, Qun
Zheng, Tianyu
Mckinstry, Karl
Abrégé
Disclosed herein are unique assay methods and devices that provide simple and quick evaluation of function, status and/or activity of an immune system of a subject. Specifically exemplified is a method that involves mixing an assay substance with a blood or blood component from the subject to form an assay product that comprises at least one unit of the assay substance and at least one molecular component of the blood or blood component; analyzing the assay product under conditions to determine an assay product property (the assay product property including a physical, chemical, optical, electrical, magnetic, and/or mechanical property); and comparing the assay product property with a correlative property of an unexposed assay substance to generate a comparative data value, wherein the comparative data value indicates the function, status and/or activity of an immune system of the subject.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Kim, Brian
White, Kevin
Mulberry, Geoffrey
Abrégé
A device comprising monolithic substrates forming a chip including a wireless, battery-less monolithically-integrated neural interface (MINI) device. The chip comprises an integrated circuit (IC) being embedded in a first monolithic substrate and comprising a plurality of amplifiers configured to amplify received neural signals from a monitored subject, and a radio data signal generator configured to process the amplified neural signals and generate a multiplexed digital signal. The chip includes radio- frequency (RF) planar coils embedded in a second monolithic substrate, being electrically connected to the IC through the first monolithic substrate, being configured for wireless transmission of the multiplexed digital signal to a remote wireless device and being configured to receive wireless power signals to power the IC. A plurality of on-chip electrodes is included to directly sense the neural signals of the subject and provide the neural signals to the plurality of amplifiers.
A61N 1/02 - SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE ÉLECTROTHÉRAPIE; MAGNÉTOTHÉRAPIE; THÉRAPIE PAR RADIATIONS; THÉRAPIE PAR ULTRASONS Électrothérapie; Circuits à cet effet - Parties constitutives
17.
NOVEL ONCOLYTIC VIRUSES FOR SENSITIZING TUMOR CELLS TO KILLING BY NATURAL KILLER CELLS
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Parks, Griffith
Copik, Alicja
Abrégé
Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
19.
PUMPLESS MICROFLUIDIC ORGAN-ON-A-CHIP SYSTEM INCLUDING A FUNCTIONAL IMMUNE SYSTEM
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
HESPEROS, INC. (USA)
Inventeur(s)
Hickman, James
Colon, Alisha
Mcaleer, Christopher
Sasserath, Trevor
Rumsey, John
Elbrecht, Daniel
Abrégé
A pumpless microfluidic system is disclosed that can be used to mimic the interaction of organ systems with the immune system. Also disclosed is a method for mimicking an immune system, comprising culturing a plurality of organ cells and at least one population of immune cells in the disclosed pumpless microfluidic system under physiological conditions. The method can further comprise activating an immune reaction in the pumpless microfluidic system, continuing the culture for a defined period, collecting a sample of culture medium from the system, and assaying the sample for one or more indicators of an immune response.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation utilisant la micro-encapsulation, p.ex. utilisant des vésicules liposomiques
21.
METHODS AND COMPOSITIONS RELATED TO NK CELL AND ANTI-PDL1 CANCER THERAPIES
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Perez, Jesus Manuel
Santra, Santimukul
Abrégé
Disclosed are compositions comprising polymeric nanoparticles and methods of using the same. The polymeric nanoparticles can be conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein. The polymeric nanoparticles can also comprises an imaging compound and/or a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle. A cancer therapeutic composition comprising the nanoparticle is also disclosed. The disclosed nanoparticles can be used to target and deliver imaging and/or therapueitc compounds to cancer cells, thereby identifying and/or treating a solid tumor cell target. Methods for treating cancer, such as lung cancer, using the polymeric nanoparticles are also disclosed.
C08G 63/688 - Polyesters contenant des atomes autres que le carbone, l'hydrogène et l'oxygène contenant du soufre
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
23.
SYSTEMS AND METHODS FOR AUTOMATED SINOGRAM COMPLETION, COMBINATION, AND COMPLETION BY COMBINATION
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
REVVITY HEALTH SCIENCES, INC. (USA)
Inventeur(s)
Meganck, Jeff
Frenkel, Michael
Katsevich, Alexander
Abrégé
Described herein are systems and methods for automated completion, combination, and completion by combination of sinograms. In certain embodiments, sinogram completion is based on a photographic (e.g. spectral or optical) acquisition and a CT acquisition (e.g., micro CT). In other embodiments, sinogram completion is based on two CT acquisitions. The sinogram to be completed may be truncated due to a detector crop (e.g., a center-based crop or an offset based crop). The sinogram to be completed may be truncated due to a subvolume crop (e.g., based on low resolution image projected onto sinogram).
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Meganck, Jeff
Frenkel, Michael
Katsevich, Alexander
Abrégé
Described herein are systems and methods for automated completion, combination, and completion by combination of sinograms. In certain embodiments, sinogram completion is based on a photographic (e.g. spectral or optical) acquisition and a CT acquisition (e.g., micro CT). In other embodiments, sinogram completion is based on two CT acquisitions. The sinogram to be completed may be truncated due to a detector crop (e.g., a center-based crop or an offset based crop). The sinogram to be completed may be truncated due to a subvolume crop (e.g., based on low resolution image projected onto sinogram).
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE AT LAKE NONA (USA)
MEMORIAL SLOAN KETTERING CANCER CENTER (USA)
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Khaled, Annette
Perez Figueroa, Jesus Manuel
Santra, Santimukul
Kaittanis, Charalambos
Santiesteban, Oscar
Grimm, Jan
Sessions, Hampton
Abrégé
Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Zhai, Lei
Mcinnis, Matthew
Abrégé
The present invention includes a simple, scalable and solventless method of dispersing graphene into polymers, thereby providing a method of large-scale production of graphene-polymer composites. The composite powder can then be processed using the existing techniques such as extrusion, injection molding, and hot-pressing to produce a composites of useful shapes and sizes while keeping the advantages imparted by graphene. Composites produced require less graphene filler and are more efficient than currently used methods and is not sensitive to the host used, such composites can have broad applications depending on the host's properties.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Santra, Swadeshmukul
Berroth, Megan
Abrégé
Embodiments of the present disclosure, in one aspect, relate to compositions including a vacancy-engineered (VE)-ZnO nanocomposite, methods of making a composition, methods of using a composition, and the like.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Copik, Alicja J.
Oyer, Jeremiah L.
Igarashi, Robert Y.
Altomare, Deborah
Abrégé
Disclosed herein are novel compositions and methods for stimulation of and the production or expansion of natural killer (NK) cells. Numbers of NK cells can be increased following contact with exosomes modified with one or more stimulatory peptides. Methods and compositions for the production of exosomes, wherein the exosomes comprises stimulatory peptides are also described. Also described are methods of treating cancer using the disclosed NK-stimulating exosomes or NK cells stimulated by the disclosed methods.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Santra, Swadeshmukul
Das, Smruti
Rajasekaran, Parthiban
Maxwell, Tyler
Abrégé
A composition comprising a chelate-based ternary complex is useful for: (1) at least in-part disabling existing populations of microorganisms; and (2) at least in-part inhibiting growth of new microorganism populations. The chelate-based ternary complex comprises a hydrogen peroxide component, a plant compatible growth promoter component and a divalent zinc ion component. The plant compatible growth promoter component may comprise a urea component or a gluconate component or a salicylate component.
C05G 3/60 - Biocides ou conservateurs, p.ex. désinfectants, pesticides ou herbicides; Produits repoussant ou attirant les animaux nuisibles
A01N 37/36 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un contenant au moins un groupe carboxylique ou un thio-analogue, ou d'un de leurs dérivés, et un atome d'oxygène ou de soufre lié par une liaison simple, liés au même squelette carboné, cet atome d'oxygène ou de soufre ne faisant pas partie d'un groupe
A01N 37/40 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un contenant au moins un groupe carboxylique ou un thio-analogue, ou d'un de leurs dérivés, et un atome d'oxygène ou de soufre lié par une liaison simple, liés au même squelette carboné, cet atome d'oxygène ou de soufre ne faisant pas partie d'un groupe contenant au moins un atome d'oxygène ou de soufre lié à un système cyclique aromatique contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'oxygène ou de soufre liés au même système cyclique aromatique
A01N 47/28 - Urées ou thiourées contenant les groupes N—CO—N ou N—CS—N
A01N 59/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des éléments ou des composés inorganiques
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Khaled, Annette
Perez, Jesus Manuel
Bassiouni, Rania
Abrégé
Disclosed herein are compositions comprising a CT20 peptide and methods of using the disclosed compositions to treat cancers expressing chaperonin containing TCP (CCT).
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Blair, Richard
Abrégé
Existing methods of producing high quality graphene/graphite oxides are generally accomplished by exfoliating graphite into flakes and oxidizing the graphite flakes with strong oxidizers under extreme conditions and require careful purification. The oxidizers are typically strong acids used in high concentrations at elevated temperatures requiring complicated purification processes to yield oxidized graphene/sheets. The existing processes can cost up to $12,000/gram. This invention uses a mild oxidant combined with mechanical processing where the sole products are oxidized graphite/graphene and water without the need for further purification.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Hickman, James
Stancescu, Maria
Molnar, Peter
Long, Christopher
Mcaleer, Christopher
Abrégé
In an aspect, disclosed herein are physiological devices and systems, and components thereof, used to evaluate cardiac parameters and arrhythmogenic mechanisms. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Copik, Alicja
Reddy, Vijay
Oyer, Jeremiah
Abrégé
The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.
A61K 47/42 - Protéines; Polypeptides; Leurs produits de dégradation; Leurs dérivés p.ex. albumine, gélatine ou zéine
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Phanstiel, Otto, Iv
Muth, Aaron
Abrégé
Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti- metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s). Specifically exemplified are compounds covered under the following formula: wherein x = 0-6; wherein y = 3 or 4 or 5; and wherein z = 3 or 4 or 5; or a pharmaceutically acceptable salt thereof.
C07C 211/36 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné saturé contenant au moins deux groupes amino liés au squelette carboné
A61K 31/132 - Amines, p.ex. amantadine ayant plusieurs groupes amino, p.ex. spermidine, putrescine
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Phanstiel, Otto, Iv
Muth, Aaron
Abrégé
Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases. In a specific example, the compound is represented by the formula: (I) R'HN-(CH2),-NH-(CH2)y-NH-CH2-R- CH2-NH-(CH2)xx-NH- (CH2)yy-NHR" wherein R is selected from the group consisting of anthracene, naphthalene, and benzene; wherein R' and R" are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, and butyl; and wherein x, xx, y, and yy are independently selected from the group consisting of 3 and 4; or a stereoisomer, or a pharmaceutically acceptable salt thereof.
C07C 211/26 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Reid, David L.
Seal, Sudipta
Petersen, Eric
Abrégé
A method of forming composite materials includes mixing a first metal precursor with a chelating agent to form a first metal-chelate complex. The first metal-chelate complex is added to a polymer binder having terminating hydroxyl groups to form a polymer binder-first metal-chelate. The polymer binder first metal-chelate complex is mixed with an aluminum precursor. The aluminum precursor decomposes forming aluminum nanoparticles dispersed in a continuous phase material having metallic aluminum cores. At least one of the first metal-chelate complex and the first metal is dissolved in the continuous phase. The aluminum nanoparticles can have a passivating coating layer thereon provided by the polymer binder, or can have a passivating coating layer formed by including an epoxide, alcohol, carboxylic acid, or amine in the adding that forms passivating compound(s) which add further protection that can provide complete protection from oxidation of the metallic aluminum cores by air.
C06B 27/00 - Compositions contenant un métal, le bore, le silicium, le sélénium ou le tellure ou leurs mélanges, intercomposés ou hydrures avec des hydrocarbures ou des hydrocarbures halogénés
C06B 23/00 - Compositions caractérisées par des constituants non explosifs ou non thermiques
C06B 33/00 - Compositions contenant des particules de métal, alliage, bore, silicium, sélénium ou tellure avec au moins un matériau fournissant de l'oxygène, qui est soit un oxyde métallique, soit un sel, organique ou inorganique, susceptible de donner un oxyde m
C06B 43/00 - Compositions caractérisées par des constituants explosifs ou thermiques non prévus en
C06D 5/00 - Production de gaz sous pression, p.ex. pour cartouches de mine, cartouches de mise à feu, fusées
37.
METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Khaled, Annette
Boohaker, Rebecca
Lee, Michael
Figueroa, Jesus Perez
Abrégé
In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des substances chimiques des substances liquides
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Khaled, Annette
Boohaker, Rebecca
Lee, Michael
Figueroa, Jesus Perez
Abrégé
In an aspect, the invention relates to compositions and methods for penneabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Hickman, James
Guo, Xiufang
Abrégé
A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more human muscle cells in a substantially serum-free medium. A synthetic mammalian neuromuscular junction includes a human motoneuron functionally linked to a human muscle cell in a substantially serum-free medium. An artificial substrate may be used to support the one or more neuromuscular junctions.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Merchant, Stephanie
Sugaya, Kiminobu
Abrégé
Disclosed herein are novel methods and compositions for treating and/or preventing hair loss in patients. Specifically exemplified herein are compositions containing a modified pyrimidine that are topically applied to a scalp of an patient. Typically, the patient has androgenic alopecia, alopecia areata, postpartum alopecia or telogen effluvium.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Seal, Sudipta
Hench, Larry L.
Krishna Moorthy, Suresh Babu
Reid, David
Karakoti, Ajay
Abrégé
Processes and methods of making and preparing, compositions and structural products therefrom are provided, whereby the surface area of alumino-silicate based powders is greatly increased and rendered chemically active so that when the functionalized powders are mixed with water poly-condensation reactions occur between the surfaces binding the powders together to form a structural material with negligible emission of carbon compounds. In another embodiment, the surface functionalized powders can be mixed with an additive; a dry aggregate, such as sand and water to make a slurry that can be poured or cast into any desired shape and rapidly cured to a hardened shape suitable for use as a structural material with the mechanical strength equivalent to Portland-cement based concrete products. In additional embodiments, the alumino- silicate based powders are nano-functionalized and foam functionalized to provide light weight and structurally strong materials that can also be used in combination with or as a replacement for Portland-cement.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
YALE UNIVERSITY (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventeur(s)
Turkson, James
Hamilton, Andrew D.
Jove, Richard
Sebti, Said M.
Abrégé
A small-molecule Stat3 dimerization inhibitor, S3I-M2001. is described and the dynamics of intracellular processing of activated Stat3 within the context of the biochemical and biological effects of the Stat3 chemical probe inhibitor are elucidated. S3I-M2001 is a newly-identified oxazole-based peptidomimetic of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide that selectively disrupts active Stat3:Stat3 dimers. Stat3-dependent malignant transformation, survival, and migration and invasion of mouse and human cancer cells harboring persistently-activated Stat3 were inhibited by S3I-M2001. S3I-M2001 inhibited Stat3-dependent transcriptional regulation of tumor survival genes, such as Bcl-xL. The disclosed compound is useful as a new potential treatment for certain cancers.
brevets
